^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) + Libtayo (cemiplimab-rwlc) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1269P-EMPOWER-lung-Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)
Published date:
09/14/2020
Excerpt:
Patients with advanced NSCLC were randomised (1:1:1; stratified by histology and PD-L1 status) to receive cemiplimab 350 mg once every 3 weeks (Q3W) (Arm A); or cemiplimab 350 mg Q3W plus ipilimumab 50 mg once every 6 weeks (Q6W) (up to 4 doses) (Arm B); or cemiplimab 1050 mg Q3W (Arm C), for up to 108 weeks or until disease progression....For patients with PD-L1 levels <1%, ORR was 36.4% (Arm B), and 11.1% (Arm C)...
Trial ID:
